Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)

NCT ID: NCT06315725

Last Updated: 2024-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-12

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time.

Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level.

To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study.

Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes (T1D) Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sweet taste perception with/without sweet taste blockade

In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with a diagnosis of T1D
* HbA1C ≤ 8 %
* Insulin pump therapy
* Adults of any gender or biological sex aged 18-45 years old,
* Body Mass Index (BMI) between 18.5-29.9 kg/m,
* Non-smokers,
* English or French speaker. ●. Who can consume chicken and fish

Exclusion Criteria

* A major medical diagnosis that could potentially influence metabolic dysfunction
* A major medical diagnosis other than T1D,
* Alcohol or substance use disorder,
* Eating disorder or history of malabsorptive syndrome,
* Inflammatory bowel disease,
* Self-reported impairment in taste or smell,
* A known taste or smell dysfunction (e.g., anosmia),
* Active pregnancy and/or lactation,
* Food allergies or intolerances,
* Dislike of the test beverages,
* History of bariatric surgery at any point in the past ●. Regular consumer of Gymnema sylvestre
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dana Small

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Innovative Medicine, The Research Institute of the McGill University Health Centre

Montreal, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Golnaz Arjmand, PhD

Role: CONTACT

514-398-3020

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Golnaz Arjmand, Postdoctoral Researcher

Role: primary

514-398-3020

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-10504

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.